PE pivots to MedTech as hospital valuations soar; diagnostics gains - Business Standard

Private equity investors are meaningfully rebalancing their healthcare allocations away from hospital assets toward medical devices and diagnostics, according to senior fund managers tracking India's healthcare investment landscape. While hospitals have historically commanded PE interest due to rising insurance penetration and structural capacity shortages, valuations in this subsector have elevated substantially over the past two to three years, prompting sophisticated capital allocators to seek returns in less saturated segments with more attractive entry multiples.

Mayur Sirdesai, founding partner at Somerset Indus, highlighted the strategic pivot underway: investors are now establishing MedTech platforms designed to roll up smaller device businesses, while simultaneously revisiting diagnostics as valuations have compressed relative to hospital assets. This diversification reflects rational capital allocation discipline—hospitals remain sound investments fundamentally, but their valuations now leave limited margin for error. Diagnostics benefits from both structural appeal (fewer public market competitors, cleaner exit pathways) and cyclical repricing following a period of underinvestment relative to other healthcare verticals.

Tata Capital Healthcare Fund's investment thesis reinforces this narrative. Medical devices are capturing institutional attention due to converging tailwinds: strong domestic demand, import substitution gains as Indian manufacturers capture share from foreign competitors, and export expansion into developed markets. CDMOs have become particularly compelling amid the China Plus One manufacturing diversification trend, where multinational pharmaceutical firms systematically redistribute contract manufacturing away from China and toward alternative jurisdictions including India. This structural shift creates durable demand for CDMO capacity and expertise.

The healthcare sector as a whole continues to experience robust PE activity, with capital flowing across pharmaceuticals, hospitals, and diagnostics. However, the direction of marginal capital has clearly shifted toward higher-growth, less-saturated subsectors. Hospital valuations, while still investable on fundamentals, have priced in a portion of the sector's structural upside, whereas MedTech and diagnostics platforms offer more attractive risk-reward profiles for new capital deployment. This rotation reflects disciplined capital allocation in response to changing relative valuations rather than any deterioration in underlying healthcare demand or demographic tailwinds in India.